Particularly, the association of elexacaftor (a CFTR corrector), tezacaftor (a CFTR corrector), and ivacaftor (a CFTR potentiator) has been tested in clinical trials in CF patients with at least one F508del-CFTR allele [8,9,10,11]. Here, CFTR is linked to cystic fibrosis.